Biography

Eric Nuermberger, MD is Professor of Medicine at Johns Hopkins University. His research is focused on translational drug and regimen development for TB and other mycobacterial infections. This work has informed the clinical development of a number of new and repurposed drugs and novel regimens, including including HPZM and BPaL for treatment and 1HP and a long-acting formulation of bedaquiline for TB prevention. He is currently a principal investigator for the BREACH-TB trial evaluating a short-course regimen of oral bedaquiline for TB prevention. Dr. Nuermberger has served as an Associate Editor of Antimicrobial Agents and Chemotherapy and the International Journal of Tuberculosis and Lung Disease and as a member of TB Transformative Science Group of the ACTG, the Core Science Group of the CDC TB Trials Consortium and the Scientific Advisory Committee of the TB Alliance.